[New perspectives on oral preventive anticoagulants].
作者信息
Enfedaque Montes Belén, Sant i Arderiu Elisenda
出版信息
Aten Primaria. 2010 Apr;42(4):194-5. doi: 10.1016/j.aprim.2009.11.007. Epub 2010 Feb 1.
Abstract
摘要
相似文献
1
[New perspectives on oral preventive anticoagulants].[口服预防性抗凝剂的新视角]
Aten Primaria. 2010 Apr;42(4):194-5. doi: 10.1016/j.aprim.2009.11.007. Epub 2010 Feb 1.
2
Viewpoint: oral anticoagulation in heart disease.观点：心脏病中的口服抗凝治疗
Circulation. 2006 Jul 4;114(1):f101-2.
3
Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin.
Stroke. 2003 Jan;34(1):234-5. doi: 10.1161/01.str.0000047035.04395.ed.
4
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.口服抗凝剂。作用机制、临床疗效及最佳治疗范围。
Chest. 1992 Oct;102(4 Suppl):312S-326S. doi: 10.1378/chest.102.4.312s.
5
New oral anticoagulants and oculoplastic surgery.新型口服抗凝药物与眼整形手术。
Can J Ophthalmol. 2014 Apr;49(2):123-7. doi: 10.1016/j.jcjo.2013.11.007. Epub 2014 Feb 21.
6
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease?口服抗凝治疗在外周动脉疾病患者中是否有作用？
Curr Drug Targets Cardiovasc Haematol Disord. 2004 Sep;4(3):269-73. doi: 10.2174/1568006043336005.
7
8
Oral anticoagulants in arterial disease.动脉疾病中的口服抗凝剂。
Br Med Bull. 1978 May;34(2):177-82. doi: 10.1093/oxfordjournals.bmb.a071489.
9
Is the ideal anticoagulant a myth?理想的抗凝剂是神话吗？
Expert Rev Clin Pharmacol. 2012 May;5(3):231-6. doi: 10.1586/ecp.12.18.
10
Guidelines on oral anticoagulation: third edition.
Br J Haematol. 1998 May;101(2):374-87. doi: 10.1046/j.1365-2141.1998.00715.x.
本文引用的文献
1
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
2
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.新型口服抗栓药物的出现：对其临床潜力的批判性评估。
Vasc Health Risk Manag. 2008;4(6):1373-86. doi: 10.2147/vhrm.s3266.
3
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].新型口服抗凝剂：分子特征、作用机制、药代动力学和药效学
Med Clin (Barc). 2008 Nov;131 Suppl 2:66-9. doi: 10.1016/s0025-7753(08)76452-2.
4
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).心房颤动的抗栓治疗：美国胸科医师学会循证临床实践指南（第8版）
Chest. 2008 Jun;133(6 Suppl):546S-592S. doi: 10.1378/chest.08-0678.
5
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).静脉血栓栓塞的预防：美国胸科医师学会循证临床实践指南（第8版）
Chest. 2008 Jun;133(6 Suppl):381S-453S. doi: 10.1378/chest.08-0656.
6
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).新型抗血栓药物：美国胸科医师学会循证临床实践指南（第8版）
Chest. 2008 Jun;133(6 Suppl):234S-256S. doi: 10.1378/chest.08-0673.
7
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.抗凝治疗的现状与未来展望：Xa因子和IIa因子抑制剂
Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023.
8
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.达比加群酯与依诺肝素预防全髋关节置换术后静脉血栓栓塞的随机、双盲、非劣效性试验
Lancet. 2007 Sep 15;370(9591):949-56. doi: 10.1016/S0140-6736(07)61445-7.
Zotero 插件